mRNA vaccine
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo
NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA
There are currently no approved human vaccines for Lyme disease
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients
Over 800,000 people worldwide live with haemophilia
Pfizer’s PADCEV gets FDA approval for bladder cancer
Bladder cancer affects more than 614,000 people globally each year
Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk
The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer